## CONTRACEPTIVES TIER EXCEPTION REQUEST

PRESCRIBER FAX FORM



ONLY the prescriber may complete this form. This form is for prospective, concurrent, and retrospective reviews. By submitting this form, you attest that all information provided is true and accurate.

PLEASE NOTE: Incomplete forms will be returned for additional information.

To ensure you are submitting this form correctly, complete and submit it directly to Prime Therapeutics (see details at the end of this form) or submit it online at <a href="https://www.covermymeds.com">www.covermymeds.com</a>. For formulary information, please visit <a href="https://www.myprime.com">www.myprime.com</a>.

City, State:  Group Number:  Prescriber Last Name:  City, State:  Contact Name:  City, State:  BER INFORMATION (IF APPLIPrescriber Last Name:	NPI: Phone	ZIP:		DB (mm/dd/yyyy):  tient Phone:  Specialty:  Secure Fax:			
Group Number:  N Prescriber Last Name: Contact Name: City, State: BER INFORMATION (IF APPLI	Phone		Pa	Specialty:			
Prescriber Last Name: Contact Name: City, State: BER INFORMATION (IF APPLI	Phone	:					
Prescriber Last Name:  Contact Name:  City, State:  BER INFORMATION (IF APPLI	Phone	:					
Contact Name:  City, State:  BER INFORMATION (IF APPLI	Phone	:					
City, State: BER INFORMATION (IF APPLI		:		Secure Fax:			
BER INFORMATION (IF APPLI	ICABLE)						
	ICABLE)	ZIP:					
Proporihor Lost Namo:							
rescriber Last Name.	NPI:	NPI:		Specialty:			
Contact Name:	Phone	Phone: Secure Fax:					
City, State:	I	ZII			ZIP:		
ATTACH ADDITIONAL INFOR	RMATION AS NE	EDED.					
gnosis with ICD-9 Code: ICD-10 Code:							
Dosing Schedule:				Quantity per Month:			
has previously tried and failed	for the treatment	of this diagn	osis:				
Date range:			Date range:				
Date range:			Date range:				
Date range:			Date range:				
e requested agent?				□ Ye	s 🗆 N		
	_	-					
	• •	•	•		s 🗆 N		
					s 🗆 N		
- ·	-	-	-		g dose		
	City, State:  ATTACH ADDITIONAL INFORM  has previously tried and failed range: ange: ange: ange: be requested agent? cle, topical or vaginal contrace rention of pregnancy as the main research agent?  erequested medication, strength	City, State:  ATTACH ADDITIONAL INFORMATION AS NEI  ICD-10  has previously tried and failed for the treatment of ange:  ange:  ange:  be requested agent?  cle, topical or vaginal contraceptive being used for the information of pregnancy as the main purpose of the information of pregnancy as the information of pregnancy as the main purpose of the information of pregnancy as the main purpose of the information of pregnancy as the main purpose of the information of pregnancy as the main purpose of the information of pregnancy as the main purpose of the information of pregnancy as the information of pregnancy as the main purpose of the information of pregnancy as the information of pre	City, State:  ATTACH ADDITIONAL INFORMATION AS NEEDED.  ICD-10 Code:  has previously tried and failed for the treatment of this diagnorange: ange: ange: be requested agent?  cole, topical or vaginal contraceptive being used for contraceptention of pregnancy as the main purpose of the request to an expension of pregnancy as the pregnancy as th	City, State:  ATTACH ADDITIONAL INFORMATION AS NEEDED.  ICD-10 Code:  has previously tried and failed for the treatment of this diagnosis: range:	City, State:  ATTACH ADDITIONAL INFORMATION AS NEEDED.    CD-10 Code:     Quantity per Month:     has previously tried and failed for the treatment of this diagnosis:     ange: Date range:     ange: Date range:		

Please continue to the next page.

Patient First Name:	Patient Last Nam	ne:	MI:	DOB (mm/dd/yyyy):				
			-					
Please indicate:								
☐ Date of service (if applicable	e): (mm/dd/yyyy)	):						
☐ Start of treatment: Start date	te (mm/dd/yyyy):							
☐ Continuation of therapy: Date of last treatment (mm/dd/yyyy):								
What is the priority level of this request?								
☐ Standard								
☐ Urgent (NOTE: Urgent is defined as when the prescriber believes that waiting for a standard review could seriously harm								
the patient's life, health, or ability to regain maximum function.)  If yes: Please specify:								
If yes: Please specify: _								
Please fax or mail this form to:		CONFIDENTIALITY NOTIC	E: This communic	cation is intended only for the use				
Prime Therapeutics LLC				l, and may contain information that				
Clinical Review Department		is privileged or confidential. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone at						
2900 Ames Crossing Road								
Eagan, MN 55121								
TOLL FREE				ge to Prime Therapeutics via U.S.				
FAX: 855-212-8110 PHONE:	888-271-3183	Mail. Thank you for your cooperation.						